Eagle Pharmaceuticals focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company was founded in 2007 and is based in Woodcliff Lake, New Jersey.
EGRX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for EGRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Eagle Pharmaceuticals Inc ranked in the 50th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 19.17%. The most interesting components of our discounted cash flow analysis for Eagle Pharmaceuticals Inc ended up being:
The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than merely 15.76% of the free cash flow producing stocks we're observing.
As a business, Eagle Pharmaceuticals Inc experienced a tax rate of about 36% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 92.45% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Eagle Pharmaceuticals Inc? See AMED, SNY, INBP, QDEL, and LCI.
Eagle Pharmaceuticals (EGRX) approved a $25M accelerated share repurchase transaction with JPMorgan as part of the existing $160M share repurchase program. $25M share repurchase would represent ~5% of the basic outstanding shares.Upon completion of the ASR, Eagle will have bought back a total of approximately $205 million of its stock...
Eagle Pharmaceuticals' (EGRX) marketing partner, SymBio Pharmaceuticals has received regulatory approval for TREAKISYM ready-to-dilute ((RTD)) (250 ml) liquid formulation from the Pharmaceuticals and Medical Devices Agency ((PMDA)) in Japan.As a result, the company will receive a $5M milestone payment. Product launch is expected in January 2021.The approval covers all indications for...
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that its marketing partner, SymBio Pharmaceuticals Limited (“SymBio”), has received regulatory approval for TREAKISYM ready-to-dilute (“RTD”) (250 ml) liquid formulation from the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan. The approval covers all indications for which TREAKISYM is currently approved (low-grade non-Hodgkin’s lymphoma, mantle cell lymphoma
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming conferences in September. At the Morgan Stanley 18th Annual Virtual Global Healthcare Conference: Date: Monday, September 14, 2020 Time: 3:00 p.m. Eastern Time Webcast: https://morganstanley.webcasts.com/starthere.jsp?ei=1362588&tp_key=91c8ad632b At the
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that preclinical research on dantrolene sodium was published today in the peer-reviewed Journal of Alzheimer’s Disease.1 The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimer’s disease. Eagle markets a formulation of dantrolene sodium but did